الانتقال إلى المحتوى الرئيسي
xMedica

NCT05922878ClinicalTrials.gov

Study of ALTO-300 in MDD

A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder

قيد التجنيديقبل مشاركين الآن، وفقاً لسجل السجل.
التواصل مع هذه الدراسة

باختصار

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

المرحلة 2مطلوب 325 مشاركاً75 موقعاًدولة واحدة

الفئات

مسجَّلة في سجل واحد

يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.

تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.

هل أنت مهتم بهذه الدراسة؟

تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 20 days after the recorded start)First posted 2023-06-28; recorded start 2023-06-08
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 4 other studies in this databaseCounted from the lead sponsor named in the record (Alto Neuroscience)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 45 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 325 participants (target), run at 75 sites.

How this score is built
  • Enrolment24/40

    321 participants (target)

  • Site count19/25

    45 sites

  • Country count0/15

    Single country

  • Planned duration8/10

    Planned over about 42 months

  • Sponsor scale2/10

    Alto Neuroscience has led 5 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

ملخص

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

الحالات

  • Major Depressive Disorder

الأهلية

الأهلية
الجنسالجميع
الأعمار18 Years – 70 Years
المتطوعون الأصحّاءلا

الأهلية كما كُتبت في السجل

Inclusion Criteria: * Have a diagnosis of moderate to severe major depressive disorder (MDD) * At Visit 1, currently taking a stable dose of 1 or 2 antidepressants (e.g., SSRI, SNRI, bupropion, or gepirone) for at least 6 weeks with no dose modifications in the past 2 weeks by Visit 2 * Willing to comply with all study assessments and procedures * Must not be pregnant or breastfeeding at time of enrollment or throughout study Exclusion Criteria: * Evidence of unstable medical condition * Nightly use of sleep medication * Diagnosed bipolar disorder, psychotic disorder, or dementia * Current moderate or severe substance use disorder * Has a history of hypersensitivity or allergic reaction to ALTO-300 or any of its components/excipients * Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device

الأهلية في عبارات بسيطة

لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.

تصميم الدراسة

تصميم الدراسة
نوع الدراسةتدخّلية
المرحلةالمرحلة 2
التخصيصمعشّاة
نموذج التدخّلPARALLEL
الغرض الأساسيTREATMENT
التعميةQUADRUPLE (4)
التجنيدمطلوب 325 مشاركاً

الجهة الراعية والمتعاونون

  • Alto Neuroscience الجهة الراعية

الأذرع والتدخلات

  • ALTO-300EXPERIMENTAL

    Participants will receive ALTO-300 25mg capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period. Eligible participants who will enter the open-label (OL) treatment period will receive ALTO-300 capsule once daily in the evening from OL baseline until the end of OL period/early termination visit (Up to 8 weeks).

  • PlaceboPLACEBO_COMPARATOR

    Participants will receive matching placebo capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period.

التدخلات

  • دواء ALTO-300

    ALTO-300 capsule QD

  • دواء Placebo

    Placebo capsule QD

مقاييس النتائج

  1. مقياس النتيجة الأولي

    To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS).

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    الإطار الزمني Change over time for up to week 6

  2. مقياس النتيجة الثانوي

    To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in all randomized participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS)

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    الإطار الزمني Change over time for up to week 6

  3. مقياس النتيجة الثانوي

    To assess efficacy of adjunctive ALTO-300 versus placebo for MDD as measured by the change over time up to week 6 in response (>50% improvement from baseline) rates based on the MADRS

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    الإطار الزمني Change over time for up to week 6

  4. مقياس النتيجة الثانوي

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of the incidence, severity, and relatedness of Adverse Events.

    Incidence, severity, and relatedness of Adverse Events

    الإطار الزمني Assessed from Day 1 to Week 14

  5. مقياس النتيجة الثانوي

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Heart Rate.

    Assessment of Heart Rate

    الإطار الزمني Assessed from Day 1 to Week 14

  6. مقياس النتيجة الثانوي

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Weight.

    Assessment of Weight Change

    الإطار الزمني Assessed from Day 1 to Week 14

  7. مقياس النتيجة الثانوي

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Blood Pressure.

    Assessment of Blood Pressure

    الإطار الزمني Assessed from Day 1 to Week 14

  8. مقياس النتيجة الثانوي

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of suicidality with the Concise Health Risk Tracking Self-Report,12 item scale (CHRT-SR12).

    The CHRT is a brief, self-report measure that systematically assesses both suicidal thinking and associated thoughts that may indicate the propensity for suicidal acts. The CHRT-SR12 is a 12 item scale. The patient assigns a score of 0-4 for each item of the scale, allowing for a total score of 0 to 48, with the higher score signifying more severe symptoms.

    الإطار الزمني Assessed from Day 1 to Week 15

التواريخ

التواريخ
تاريخ البدء8 يونيو 2023 (فعلي)
الإتمام الأولي1 ديسمبر 2026 (تقديري)
الإتمام1 ديسمبر 2026 (تقديري)
أول نشر28 يونيو 2023 (فعلي)
آخر تحديث26 أكتوبر 2026
النتائج منشورةغير مذكور في سجل السجل
آخر تأكيد للحالةأكتوبر 2026

فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.

المواقع

30 موقعاً قيد التجنيد

United States

United States
المنشأةالمدينةالولاية أو المنطقةالحالة
Site 114AlbuquerqueNew Mexicoقيد التجنيد
Site 216AllentownPennsylvaniaأُنهي
Site 316AustinTexasقيد التجنيد
Site 218BellflowerCaliforniaقيد التجنيد
Site 317BlackfootIdahoمسحوب
Site 236BoiseIdahoقيد التجنيد
Site 119BoiseIdahoنشط، دون تجنيد
Site 318CarlsbadCaliforniaنشط، دون تجنيد
Site 310ChicagoIllinoisنشط، دون تجنيد
Site 202CincinnatiOhioقيد التجنيد
Site 159ClermontFloridaأُنهي
Site 207ClintonUtahنشط، دون تجنيد
Site 203Colorado SpringsColoradoنشط، دون تجنيد
Site 239ConroeTexasقيد التجنيد
Site 229Creve CouerMissouriمسحوب
Site 102DallasTexasنشط، دون تجنيد
Site 343DenverColoradoقيد التجنيد
Site 349EvergreenColoradoنشط، دون تجنيد
Site 345EvergreenColoradoنشط، دون تجنيد
Site 277FairfaxVirginiaقيد التجنيد
Site 238FayettevilleGeorgiaقيد التجنيد
Site 148Fort WorthTexasمسحوب
Site 347Fort WorthTexasأُنهي
Site 217GlendaleCaliforniaنشط، دون تجنيد
Site 279HattiesburgMississippiمسحوب
Site 199HickoryNorth Carolinaنشط، دون تجنيد
Site 320HoustonTexasقيد التجنيد
Site 275HoustonTexasقيد التجنيد
Site 215JacksonMississippiنشط، دون تجنيد
Site 335LafayetteCaliforniaقيد التجنيد
Site 335LafayetteCaliforniaقيد التجنيد
Site 344Las VegasNevadaقيد التجنيد
Site 209Los AngelesCaliforniaنشط، دون تجنيد
Site 240MankatoMinnesotaقيد التجنيد
Site 201MarreroLouisianaأُنهي
Site 219MatherCaliforniaقيد التجنيد
Site 350MediaPennsylvaniaمسحوب
Site 225Miami GardensFloridaنشط، دون تجنيد
Site 190Miami LakesFloridaنشط، دون تجنيد
Site 265MinneapolisMinnesotaقيد التجنيد
Site 194Mission ViejoCaliforniaأُنهي
Site 206Missouri CityTexasمسحوب
Site 198MonroeLouisianaأُنهي
Site 267MoorparkCaliforniaقيد التجنيد
Site 352MoosicPennsylvaniaنشط، دون تجنيد
Site 283New YorkNew Yorkقيد التجنيد
Site 319New YorkNew Yorkنشط، دون تجنيد
Site 214NorwalkConnecticutمسحوب
Site 161OkeechobeeFloridaنشط، دون تجنيد
Site 195Oklahoma CityOklahomaأُنهي

يُدرَج 25 موقعاً إضافياً في سجل السجل.

مستندات الدراسة

لا تُرتبط أي مستندات في سجل السجل هذا.

التغيّرات عبر الزمن

  1. 26 أكتوبر 2026

    تغيّر هدف التجنيد

    Enrollment target revised up from 321 to 325

    321325

  2. 26 أكتوبر 2026

    أُضيف موقع

    30 sites added (75 total)

    4575